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 Oral delivery of bioencapsulated coagulation factor IX
 prevents inhibitor formation and fatal anaphylaxis in
 hemophilia B mice
 Dheeraj Vermaa\ Babak Moghimib,1# Paul A. LoDucab, Harminder D. Singh3, Brad E. Hoffmanb, Roland W. Herzogb'2,
 and Henry Daniell3'2
 aDepartment of Molecular Biology and Microbiology, College of Medicine, University of Central Florida, Orlando, FL 32816-2364; and department of
 Pediatrics, College of Medicine, University of Florida, Gainesville, FL 32610
 Edited by Charles J. Arntzen, Arizona State University, Tempe, AZ, and approved March 3, 2010 (received for review October 22, 2009)
 To address complications of pathogenic antibody or life-threatening
 anaphylactic reactions in protein replacement therapy for patients
 with hemophilia or other inherited protein deficiencies, we have
 developed a prophylactic protocol using a murine hemophilia
 B model. Oral delivery of coagulation factor IX fused with cholera
 toxin p-subunit (with or without a furin cleavage site; CTB-FFIX or
 CTB-FIX), expressed in chloroplasts (up to 3.8% soluble protein or 0.4
 mg/g leaf tissue), bioencapsulated in plant cells, effectively blocked
 formation of inhibitory antibodies (undetectable or up to 100-fold
 less than controls). Moreover, this treatment eliminated fatal ana
 phylactic reactions that occurred after four to six exposures to intra
 venous F.IX. Whereas only 20-25% of control animals survived after
 six to eight F.IX doses, 90-93% of F.IX-fed mice survived 12 injections
 without signs of allergy or anaphylaxis. Immunostaining confirmed
 delivery of F.IX to Peyer^s patches in the ileum. Within 2-5 h, feeding
 of CTB-FFIX additionally resulted in systemic delivery of F.IX antigen.
 This high-responder strain of hemophilia B mice represents a new
 animal model to study anaphylactic reactions. The protocol was
 effective over a range of oral antigen doses (equivalent to 5-80 pg
 recombinant F.IX/kg), and controlled inhibitor formation and ana
 phylaxis long-term, up to 7 months (-40% life span of this mouse
 strain). Oral antigen administration caused a deviant immune re
 sponse that suppressed formation of IgE and inhibitory antibodies.
 This cost-effective and efficient approach of antigen delivery to the
 gut should be applicable to several genetic diseases that are prone to
 pathogenic antibody responses during treatment.
 allergy | chloroplast | genetic disorders | oral tolerance | plant-made
 therapeutics
 Current treatment of the X-linked bleeding disorder hemophilia is based on intravenous (i.v.) infusion of recombinant or plasma
 derived coagulation factor VIII (hemophilia A) or factor IX (hemo
 philia B) concentrate. In a subset of patients, humoral immune re
 sponses to the functional protein develop and pose a serious com
 plication for factor replacement therapy. In hemophilia A, formation
 of inhibitory antibodies (inhibitors) directed against factor VIII
 (F.VTII), a helper-T-cell-dependent response, occurs in 20-30% of
 patients (1). There is much progress in the risk assessment of inhibitor
 formation in patients early in therapy, using a combination of geno
 typing (e.g., determination of the underlying F.VIII mutation and
 polymorphisms in the promoters of the cytokine genes IL-10 and
 TNFoc), family history of inhibitor formation, ethnicity, and intensity
 of early treatment (2). Inhibitors increase the risk for bleeding-related
 morbidity and mortality. High-titer inhibitors (>5 Bethesda units,
 BU/mL) prevent treatment with clotting factor product. Bypass re
 agents, such as activated factor VII, are expensive and pose throm
 botic risks. Inhibitors can be eliminated by immune tolerance in
 duction (ITI) protocols, which are based on frequent high-dose
 infusions of factor for months to several years, and often require
 amounts of products exceeding $1,000,000.
 The overall incidence of inhibitors is considerably lower in he
 mophilia B (1.5-3%). However, 9-23% of patients with severe dis
 ease (<1% coagulation activity) form inhibitors, which are typically
 high-titer and are almost exclusively confined to subjects with gene
 deletions or early stop codons (3). ITT protocols are less effective for
 treatment of inhibitors to factor IX (F.IX) and sometimes have to be
 interrupted because of development of nephrotic syndrome. Impor
 tantly, studies found that up to 50% of patients with F.IX inhibitors
 may experience potentially ltfe-threatening anaphylactic reactions to
 F.IX which also preclude the subject from home treatment and
 severely hinder ITI protocols (3). These acute severe and systemic
 type I hypersensitive allergic reactions, often attributed to IgE for
 mation, have been reported for treatment of hemophilia A and B,
 lysosomal storage disorders, and others (4-9). fro prophylactic pro
 tocols are currently available for prevention of these pathogenic
 antibody responses.
 Oral delivery of coagulation factors has long been discussed as a
 potential approach to induce tolerance in hemophilia (10). However,
 realization has been elusive, likely because of inefficient delivery of
 the antigen to the gut-associated lymphoid tissue (GALT). There
 fore, we sought to develop an alternative approach, using trans
 plastomic technology as a means of efficient and potentially tolero
 genic oral delivery of F.IX. This technology for robust expression and
 bioencapsulation of therapeutic proteins is based on transformation
 of plant cells by particle bombardment of plasmid DNA followed by
 homologous recombination with chloroplast genomes, selection, and
 regeneration of plants (11, 12). Transplastomic plants lack gene
 silencing, regardless of accumulating > 100-fold higher transcripts
 than in nuclear transgenic plants and accumulation of foreign pro
 teins at levels >70% of total leaf protein (13-16). Consequently, we
 and others have been able to produce high levels of several bio
 pharmaceutical proteins and vaccine antigens via the chloroplast
 system (11,17). Foreign proteins expressed in plant chloroplasts can
 be efficiently delivered to the immune or circulatory system upon oral
 delivery when they are fused with the transmucosal carrier cholera
 toxin B subunit (CTB) (14,18,19).
 Although the prokaryotic nature of the chloroplast may not
 perform all of the posttranslational modifications required to pro
 duce biologically active F.IX, we reasoned that optimal delivery of
 the polypeptide to the GALT via bioencapsulation by the plant cell
 would result in tolerogenic antigen presentation that modulates
 immune response upon i.v. administration of functional F.IX pro
 tein. Results demonstrate that repeated oral delivery of chloroplast
 derived F.IX suppressed inhibitor development and prevented life
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 threatening anaphylactic reactions to F.IX replacement therapy in a
 murine model of hemophilia B.
 Results
 Construction of Chloroplast Transformation Vector. Both chloroplast
 vectors pLD CTB-FIX and pLD CTB-FFIX (Fig. L4) used in this
 study are based on the universal chloroplast vector pLD-Ctv that
 targets the expression cassette into the spacer region between the trnl
 and trnA genes of the chloroplast genome for integration via ho
 mologous recombination (20). In the CTB-FIX construct, a glycine
 proline-glycine-proline (GPGP) hinge was created between the
 fusion elements to prevent steric hindrance, whereas in the CTB
 FFIX construct, along with the GPGP hinge, a furin cleavage site was
 also introduced. The CTB-FIX and CTB-FFIX fusion genes were
 regulated by thepsbA promoter and 5' untranslated region (UTR) to
 achieve hyperexpression, as demonstrated previously for several
 other transgenes (21). The psbA 3' UTR placed at the 3' end of the
 fusion gene imparted transcript stability. The aadA gene driven by the
 tobacco plastid ribosomal operon promoter (?rrn) and the GGAG
 ribosome binding site conferring spectinomycin resistance were used
 for selection.
 Regeneration of Transplastomic Plants and Evaluation of Transgene
 Integration by Southern Blot Analysis. Transplastomic tobacco
 plants were produced as described earlier (12, 22). Chloroplast
 transgenic lines were examined by Southern blots to confirm site
 specific transgene integration and to determine homoplasmy or
 heteroplasmy. Digestion of total plant DNA from untransformed
 plants (WT) with Hindlll generated a 7.67-kbp fragment when
 hybridized with the 32P-labeled trnl-trnA flanking sequence probe,
 indicating no integration of foreign DNA (Fig. 1 B and C). All
 CTB-FIX transplastomic lines showed both 10.88-kb and 7.67-kb
 fragments, indicating heteroplasmy, whereas all CTB-FFIX
 transgenic lines showed only the 10.89-kb fragment, indicating
 homoplasmy. Southern blots confirmed site-specific integration of
 the transgenes into the spacer region between the trnl and trnA
 genes (Fig. 1B and C). Homoplasmy in CTB-FIX transgenic lines
 was not achieved even after additional rounds of selection. This
 may be due to toxicity created by improperly folded F.IX due to
 steric hindrance in the absence of a furin cleavage site (GPGP
 pLD CTB-FIX Smal Xba I
 E^f tml ^fP^ MdA ^'5liTR)[CTBtl Factor PC 3'UTR^)j tmA~^>
 pLD CTB-FFIX Smal Xba I
 B 1 2 3 WT ^ WT 1 2 3 4
 wS* ^^o.?K?
 " : 7 67 kb
 4^ 41 F kDa WT Y MO 75
 Dctb Ab m%% mm* kDa WT Y M O. 50 75 _ 75
 "* " *
 7* F CTB CTB WT
 FIX Ab kDa FRX RX
 50 CTBAb460 ,^ 268
 Fig. 1. Characterization of transplastomic plants. (A) Schematic repre
 sentation of chloroplast transformation vectors. Prrn, rRNA operon pro
 moter; aadA, aminoglycoside 3'-adenylyltransferase gene; 5' UTR, promoter
 and 5' untranslated region of psbA gene; 3' UTR, 3' untranslated region of
 psbA gene. (B and C) Southern blot analysis of CTB-FIX and CTB-FFIX. WT,
 untransformed; 1-4, transplastomic lines. (D and E) Western blot analysis of
 transplastomic lines expressing CTB-FIX and CTB-FFIX probed, with CTB
 antibody and FIX antibody. WT, untransformed plant extract; Y, M, and O,
 plant extract from young, mature, and old transplastomic leaves, respec
 tively. (F) Native PAGE. Total soluble protein extracted from transplastomic
 leaves, resolved by native PAGE and probed with CTB antibody.
 alone was inadequate to prevent steric hindrance). Transplastomic
 lines with roots were transferred to jiffy pellets and kept under high
 humidity initially for 2 weeks in a growth chamber before plants
 were moved to the greenhouse.
 CTB-FIX and CTB-FFIX Expression and Pentamer Assembly in Transgenic
 Tobacco. Immunoblots probed with CTB antibody showed the
 presence of an ~58-kDa fusion protein in both CTB-FIX and CTB
 FFIX transplastomic lines. A similar banding pattern was observed
 by immunodetection with FIX antibody (Fig. 1D and E). Pentamer
 formation was observed in the native PAGE using CTB primary
 antibody (Fig. IF). Quantitation of the fusion protein was carried
 out by densitometry on Western blots of plant samples using known
 amounts of purified CTB. The expression levels varied significantly
 depending on the developmental stages and time of leaf harvest
 (Fig. 2 A-C). Young (top five), mature (fully grown), and old
 (bottom three) leaves in transplastomic plants were investigated.
 Fig. 2 A-C show that transplastomic lines have higher F.IX
 expression in mature leaves. Younger leaf cells contain fewer chlo
 roplasts and the psbA promoter is developmental^ regulated;
 therefore, expression levels were less than in mature leaves. Older
 senescent leaves had lower accumulation of F.IX, probably due to
 higher proteolytic activity. Likewise, F.IX expression was higher at
 6 PM than at 10 AM because the psbA promoter and 5' untranslated
 regions located upstream of the FIX gene cassette are known to
 enhance translation in the light (15,16,23). Transplastomic lines of
 CTB-FIX and CTB-FFIX had expression levels of up to 0.19% and
 3.8% (0.4 mg/g of leaf tissue) fusion protein, respectively, in the total
 soluble protein. Introduction of the furin cleavage site clearly sta
 bilized FIX and enhanced its accumulation 20-fold.
 Vibrio cholerae secretes an 86-kDa toxin that is made up of two
 subunits, an a- and a p-subunit (CTB), that contains a binding site for
 the plasma membrane receptor of the intestinal epithelial cells (GM1)
 (24,25). GMl-ganglioside has been shown to be the receptor for CTB
 protein in vivo (24), and a pentameric structure is required for binding
 to GM1 receptor (25). As illustrated in Fig. 2D, GM1 ELISA confirms
 that CTB-FIX and CTB-FFIX fusion proteins assembled properly to
 form pentameric structures within chloroplasts, which are essential
 for GMl-ganglioside receptor binding. This assay along with native
 PAGE confirmed the correct folding and disulfide-bond formation of
 CTB pentamers within transgenic chloroplasts.
 Oral Delivery of F.IX Transplastomic Leaves Suppresses Inhibitor
 Formation and Fatal Anaphylaxis in Hemophilia B Mice. Hemo
 philia B mice with targeted F9 gene deletion on C3H/HeJ genetic
 background form robust immune responses to human F.IX (hF.IX)
 upon protein or gene therapy (26). Therefore, three experimental
 groups received oral gavage of frozen powdered leaves (250 mg/
 dose) twice per week for 2 months, using leaves from untransformed
 (WT), CTB-FIX, or CTB-FFIX transplastomic plants (repre
 illrti rli ll bIf rli fli 10AM 2PM 6PM 10AM *PM 6PM
 fell 8U_ 10AM 2PM 6PM CTB-mX CTB-HX WT BSA
 Fig. 2. Protein analysis in transplastomic tobacco plants. Accumulation of
 CTB-FFIX (A and B) and CTB-FIX (C) as a function of light and developmental
 stage. (D) GM1 binding assay of CTB-FIX and CTB-FFIX tobacco transformants.
 WT, untransformed; BSA, negative control. TSP, total soluble protein.
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 senting the equivalent of 0, 0.14, and 2 ug of recombinant
 hF.IX-dose^-mouse"1, respectively). Dosage of CTB-FIX and
 CTB-FFIX for each batch of ground leaf powder was determined
 before each gavage and uniform doses were delivered. After
 1 month, a therapeutic dose of recombinant hF.IX was given i.v.
 once per week (1 IU per mouse) for 2 months, that is, extending
 1 month beyond the feeding protocol (Fig. 3A). Two more groups
 received i.v. injections of hF.IX only, without feeding.
 In unfed animals (n = 11), severe allergic reactions were observed
 starting with the fourth i.v. injection of hF.IX, at which time fatal
 anaphylactic reactions started to occur, and continued subsequently
 with an incidence of 17-33% (Fig. 3B). Similarly, WT-fed mice
 showed severe allergic reactions immediately following the fourth (2
 of 10 mice) and fifth injections (3 of 10 mice), including hunched
 position, piloerection, slowing of movement, tachypnea, and bron
 chospasms. During subsequent injections, ~50% of the mice had such
 reactions. Moreover, starting from the sixth injection, 31-40%
 of animals died within 30 min to several hours after i.v. injection of
 hF.IX, apparently from respiratory arrest (Fig. 3C). We were able to
 collect blood samples from five remaining mice immediately after the
 eighth i.v. injection, within 2 h after which three additional mice died.
 In any case, 75-80% of mice treated with hF.IX were lost within six
 to eight weekly injections (Fig. 3 B and C), unless antianaphylactic
 drugs were given (see below).
 In contrast, 90% of CTB-FIX- and 93% of CTB-FFIX-fed mice
 (n > 14 per cohort) survived the initial 2-month period of eight
 weekly hF.IX injections and even subsequent injections (total of 12
 A D ^=h
 Feeding (250 mg; twice/week) ? 100 | ******* ,******* ^ ^ ^
 Month: |-1-1-?I 3_ I | "T 0 1_2_3 ? | ^ ?I *
 hF.IX IV (onca/week) g 10 JJ. j
 Bo?i i- ' : * * : I - b I ' t J
 S ** ss?_i_ *. I"" . ahlat/aPAF ll '
 g <0" Croups: Unfed WT CTB-FIX CTB- ahW Nafve Unfed (short g I FFIX PAF term treatment) ^ n?6 n-S n?15 n=14 nM n-15 n-7
 o| I_I I_I
 012345678 Surviving control* F.IX-fed mice
 Number of Injection, [ 2mon?,0,^*mN^! ' *******-'
 Feeding (2x/>?eek) Feeding (3x/week)
 _ 100t?l. cr**m . i j i?(5?i???
 | 80- ctbto Month: 0 1 2 3 4 5 6 7
 ? gn. ;. hF.IX IV (once/week) hF]x w hF.IX IV (once/week)
 I <* i jj i I 20- '* WT | 1 3 /i\ a. _ | m 2 / \ 123456789 10 11 12 S 1 ' ^
 Number of Injections 0 1 2 3
 Time point
 Fig. 3. Prevention of inhibitor formation and of anaphylactic reactions
 against i.v. hF.IX by oral administration of hF.IX chloroplast transgenic plant
 material in hemophilia B mice. (A) Feeding and hF.IX administration schedule.
 (8) Survival of two control groups of unfed mice (starting with n = 11, solid line,
 and n = 12 mice, dotted line). Mice of one cohort (solid line) that survived five
 injections (n = 5) received antihistamine/anti-PAF before a sixth injection of hF.
 IX (ahist/aPAF), resulting in 100% survival. (C) Survival of mice fed with WT(n =
 10 mice at the onset of protein therapy), CTB-FIX (n = 17), or CTB-FFIX (n = 15)
 plant material as a function of the number of i.v. injections of hF.IX protein. (D)
 Inhibitor titers (in BU/mL) at 3-month time-point mice (i.e., after 8 weekly i.v.
 injections of hF.IX) in unfed (pooled from several experiments), WT-fed, CTB
 FlX-fed, and CTB-FFIX-fed. Additional controls: Titers in unfed mice are shown
 that received antihistamine/anti-PAF before a sixth injection of hF.IX, that
 were naive, or that received four hF.IX administrations. For the last, arrows
 indicate animals that died after a subsequent fifth injection. Each dot repre
 sents an individual animal. Horizontal bars indicate average titers for each
 experimental group. (?) Long-term control of inhibitor formation with bio
 encapsulated hF.IX following the indicated schedule for oral administration of
 CTB-FFIX plant material and i.v. injection of hF.IX protein. Numbers indicate
 time points of blood collection. Below, average inhibitor titers (in BU/mL ?
 SEM) are graphed for the indicated time points.
 exposures; Fig. 3C). In none of these mice did we observe signs of
 allergic or anaphylactic reactions. Bethesda assays showed nearly
 complete to complete suppression of inhibitor formation in mice
 fed with CTB-FIX (1 ? 0.5 BU/mL) or CTB-FFIX (0.7 ? 0.3 BU/
 mL) as compared with background inhibitor titers in naive hemo
 philia B mice (no feeding, no treatment; 0.5 ? 0.3 BU/mL). Sur
 viving WT-fed and unfed mice had significantly higher inhibitor
 titers, which were similar for these groups and ranged from 2 to
 8 BU/mL and 2.5 to 10 BU/mL, respectively (Fig. 3D).
 We suspected that these data underrepresented protein therapy
 induced inhibitor titers in the control groups, because those mice with
 fatal hypersensitive responses likely had stronger immune responses.
 To address these points, we first analyzed plasma obtained from unfed
 hemophilia B mice after only four weekly hF.IX injections. These
 had substantially higher inhibitor titers of 8-90 BU/mL (Fig. 3D), and
 the three of seven mice with the highest titers died after the fifth hF.IX
 administration (arrows in Fig. 3D). Second, five mice that had sur
 vived a fifth injection received the sixth dose of hF.IX under coverage
 with antihistamine and anti-platelet activating factor (PAF). In this
 case, all five mice survived without allergic or anaphylactic response
 (Fig. 3B). Inhibitor titers were measured in four of these mice and
 were very high (29-87 BU/mL; Fig. 3D).
 Oral Administration of Bioencapsulated hF.IX Can Control Inhibitor
 Formation Long Term. One month after the last hF.IX injection,
 one additional i.v. administration of hF.IX was performed in nine
 CTB-FFIX-fed mice (i.e., 2 months after the last feeding; Fig. 3E).
 This resulted in an increase of inhibitors to an average of 4 BU/mL
 (Fig. 3E). Subsequently, treatment was resumed for 1 month (i.e.,
 weekly i.v. infusions of hF.IX) while also continuing the feeding
 (three oral gavages per week). At the end of this regimen, inhibitor
titers had declined to baseline (Fig. 3E), indicating that the pro
 tocol can be used to control inhibitor formation long-term. Again,
 no allergic or anaphylactic responses were observed.
 Oral Administration of Bioencapsulated hF.IX Suppresses Formation
 of IgE and Inhibitors via an Immune Deviation Mechanism. Analysis
 of hF.IX-specific Ig formation showed that CTB-FIX/CTB-FFIX
 fed mice (and surviving WT-fed mice) had average circulating IgGl
 titers which were significantly lower when compared with control
 mice that were kept alive with antihistamine/anti-PAF (Fig. 44).
 Whereas IgGl titers in control mice correlated well with inhibitor
 titers, there was no correlation in CTB-FIX/CTB-FFIX-fed mice,
 which therefore had formed noninhibitory antibodies (Fig. 4C). The
 noninhibitory antibodies in CTB-FFIX-fed mice that formed upon
 protein therapy, in contrast to the inhibitors that developed in WT
 fed mice, did not cause enhanced clearance of i.v. infused hF.IX from
 the circulation (Fig. AF). The noninhibitory antibodies also did not
 prevent correction of coagulation activity (as determined by activated
 parti l thromboplastin time), which was raised from <1% at baseline
 to 16-25% of normal at 30 mi  after i.v. injection of 1IU hF.IX (n =
 5). Naive mice treated in parallel showed comparable results (16
 18% of normal at 30 min after treatment).
 Importantly, three of seven control mice that had received four
 injections  hF.IX had detectable IgE titers, and titers of >50 ng/mL
 were predictive of subsequent fatal responses (Fig. AB, arrows).
 Higher-ti er IgE was found in four of five analyzed mice that had
 received a s xth injection concomitant with antihistamine/anti-PAF
 (Fig. 4B). These control mice showed a correlation between high-titer
 IgGl (>40 pg/mL) and IgE formation, indicating that repeated i.v.
 administrations boosted Th2-driven antibody formation, resulting in
 activation of additional B cells with class switching to IgE (Fig. AD).
 This correlation was not seen in CT B-FFIX-fed mice, some of which
 developed IgGl titers that would have been predicted to be associ
 ated with IgE (Fig. AD). CTB-FIX/FFIX-fed mice had IgE titers
 of <40 ng/mL (the ackground of our assay) and no anaphylactic
 r sponses. Allergic reactions in rodents, although not previously
 identified in hemophilic mice, in general are caused by histamine
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 and PAF release for IgE-dependent reactions, whereas an alter
 native, IgG-dependent pathway has also been described, which,
 however, does not involve histamine (27). To address this point,
 additional control mice received hF.IX administration under cov
 erage with anti-PAF alone (i.e., without antihistamine), resulting in
 fatal anaphylaxis in all three animals tested, thereby further sup
 porting an IgE-dependent mechanism in the hemophilia B mice.
 None of the WT-fed or unfed mice formed IgG2a against hF.IX,
 thereby ruling out an IgG2a/complement-dependent mechanism of
 anaphylactoid reactions. Whereas IgG2a formation was highly vari
 able and inconsistent in CTB-FIX/CTB-FFIX-fed mice, tolerized
 mice consistently had circulating low titers of TGF-0-dependent
 antibodies IgG2b and IgA, the hallmark subclass of a mucosal anti
 body response (Fig. AE).
 CTB-FFIX Material Delivers hF.IX Antigen to the GALT and into the
 Circulation. Feeding by CTB-FIX or CTB-FFIX material by itself
 did not cause a detectable systemic antibody response against hF.
 IX. Immunostaining demonstrated that feeding resulted in deliv
 ery of hF.IX antigen to the ileum, predominantly to the interphase
 between microfold (M) cells and CD1 lc+ dendritic cells in Peyer's
 patches (Fig. 5 A and B). Within 2-5 h, feeding of CTB-FFIX
 material also resulted in systemic delivery of hF.IX antigen to the
 liver and into plasma (Fig. 5 D and F). In the case of unfed mice, no
 signal was detected in ileum (Fig. 5C) or liver (Fig. 5E).
 Discussion
 Oral tolerance for hemophilia has been discussed for the past decade
 but has not been realized, in part because of challenges in effective
 delivery of coagulation factor antigen to the gut. A recent study con
 cluded that the amount of coagulation factor required for feeding
 would be cost-prohibitive even for mouse experiments and therefore
 was not pursued (28). Here we used an alternative technology that
 allows for efficient production, bioencapsulation, and delivery of an
 tigens to the GALT (14,18,29,30).
 Human F.IX was produced at a high level in plant chloroplasts as a
 fusion protein. The CTB fusion ensures stability of the transgenic
 protein in the chloroplast, and the nontoxic B subunit exhibits specific
 and high-affinity binding to the oligosaccharide domain of ganglio
 side GM1 (a lipid-based membrane receptor), thereby tethering the
 protein to the plasma membrane of host cells of the intestinal epi
 thelium upon release from the plant cells in the ileum (18, 31).
 Priming with CTB-FIX via an oral route reduced Th2-dependent
 antibody responses against i.v. hF.IX, and in particular protected from
 IgE formation, thereby eliminating allergic and anaphylactic reac
 tions. Moreover, reintroduction of the antigen via the oral route suc
 cessfully controlled inhibitor formation long-term without a need for
 immune-suppressive drugs. Interestingly, plant materials expressing
 20-fold different antigen levels were effective, which should facilitate
 clinical translation. The furin cleavage site, which directs release and
 exocytosis of the fused protein from gut epithelia, was not required for
 treatment (but improved expression and accumulation of FIX in plant
 cells). These results imply that introduction of F.IX to the GALT was
 key to successful immune-modulatory therapy. It is generally thought
 that persistence of the antigen is required to maintain tolerance. Thus,
 it is likely that oral delivery has to be repeated beyond the induction
 phase, perhaps every 2 months, to maintain hyporesponsiveness long
 term. It should be possible to optimize the protocol so that less
 intensive repeated oral dosing is effective for maintenance.
 Repeated injections of hF.IX caused fatal reactions in most control
 animals, so that only mice survived that were either low responders or,
 possibly, spontaneously controlled the pathogenic antibody response.
 The magnitude of the antibody response was unmasked by pharma
 ceutical blockage of Wstamine release, thereby allowing animals to
 survive despite high production of IgE against hF.IX. Tests to detect
 IgE responses in patients with hemophilia have been developed, such
 as RAST (radioallergosorbent test) (9). However, there are no pro
 tocols for preventing or suppressing IgE formation, nor has there been
 an animal model that rnimics this aspect of hemophilia pathophysi
 ology. Similar to observations in humans, the strain of mice we iden
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 Fig. 5. Delivery of hF.IX antigen to the GALT and into circulation. (A-E)
 Immunostains (original magnification: 200x). (A) Peyer's patch and villi of
 ileum of CTB-FFIX-fed mouse stained for hF.IX (red), M cells (UEA-1, green),
 and CD11c (blue). Inset shows zoom-in on part of Peyer's patch with positive
 hF.IX staining. (B) Peyer's patch and villi of ileum of CTB-FFIX-fed mouse
 stained for hF.IX (red), F4/80+ macrophages (green), and nuclei (DAPI, blue).
 (C) Negative control: stain for hF.IX (red) and nuclei (DAPI; blue) in ileum of
 unfed mouse. (D and E) Stain for hF.IX (green) and nuclei (DAPI; blue) of liver
 of CTB-FFIX-fed (D) and unfed (?) mouse. (F) In two independent experi
 ments, hF.IX antigen was detectable in plasma in two of three mice 2 or 5 h
 after oral gavage with CTB-FFIX material.
 tified as prone to anaphylactic reactions has an F9 gene deletion (8). A
 lack of prior reports on anaphylactic reactions to coagulation factors
 may be because protein replacement therapy has been largely studied
 using F.VIII infusions to hemophilia A mice (which, similar to human
 treatment, is less likely to cause anaphylaxis). Hemophilia B mice were
 primarily used for gene therapy studies and/or bred on C57BL/6
 background (which shows weaker immune responses to F.IX) (32).
 Symptoms in the hemophilia B mice were similar to IgE-mediated
 severe anaphylactic reactions observed in the treatment of other ge
 netic diseases, including hemophilia A and the lysosomal storage
 disorders Pompe disease (acid oc-glucosidase deficiency) and Fabry
 disease (oc-galactosidase A deficiency) (5-7, 33). In treatment of
 hemophilia B, strong evidence has been provided for IgE-mediated
 anaphylactic reactions (9,34). However, IgG/complement-mediated
 mechanisms have also been proposed (4), and IgE formation may
 therefore not be the only source of anaphylactoid reactions in
 humans with hemophilia.
 Protection of hemophilia B mice from inhibitor and IgE responses
 involved a deviant immune response characterized by suppression of
 IgE and of high-titer IgGl, formation of nonneutralizing antibodies
 instead of inhibitors, and production of additional Ig subclasses (albeit
 at very lower titers). Interestingly, the presence of nonneutralizing
 antibodies has also been described in clinical ITI protocols (4). IL-4
 production by CD4+ T cells, that is, by Th2 cells, promotes both IgGl
 and IgE class switching. However, it has been proposed that gut
 associated regulatory T cells expressing IL-10 may suppress IgE for
 mation (35). Our findings on induction of IgG2b and IgA suggest a
 role for TGF-p, possibly derived from Th3 cells, in modulation of
 F.IX-specific B-cell activation.
 Notably, the response to the alio- or autoantigen introduced to the
 GALT by oral administration of chloroplast transgenic plant material
 modulates responses to the antigen in other tissues, which we ex
 ploited to develop oral tolerance protocols (14). The oral delivery
 protocol described here offers solutions for complications encoun
 tered with alternative strategies such as gene transfer or transient
 immune-suppressive regimens (36). Genetic manipulation poses
 risks of immunotoxicities and insertional mutagenesis; immune
 suppressive drugs have side effects and increase the risk for oppor
 tunistic infections, and long-term consequences of use in pediatric
 patients are unclear. Administration of peptides to mucosal surfaces
 has also been described, which, however, is complicated in an out
 bred population because it requires knowledge of CD4+ T-cell
 epitopes (37).
 The chloroplast system overcomes major limitations of protein
 production by elimination of highly expensive fermentation and puri
 fication systems, cold storage, transportation, and sterile injections.
 Genetically modified chloroplast genomes of most crops are mater
 nally inherited, and the absence of any reproductive structures offers
 efficient foreign gene containment (38, 39) and therefore facili
 tates their safe production in the field (23). Plant cells provide
 bioencapsulation and protect therapeutic proteins from degra
 dation in the stomach from acids and enzymes (30). Plants also
 reduce concerns about pathogen contamination as may be the case
 for production of proteins in transgenic animals. Whereas these
 initial studies were carried out in nonfood tobacco plants, the let
 tuce chloroplast transformation system has been well-developed
 for expression of human therapeutic proteins (14,16).
 With the recent development of novel protein replacement
 therapies for genetic diseases, more reports are coming forward on
 immunotoxicities caused by protein infusion. Oral administration
 of transplastomic plant tissue provides an avenue for prevention
 and control of pathogenic antibody responses and anaphylactic
 reactions to systemically delivered therapeutic proteins.
 Mat rials and Methods
 Vector Construction. Two CTB fusion constructs were made with human factor
 IX (FIX). To prevent steric hindrance, a glycine-proline-glycine-proline (GPGP)
 hinge was introduced between the CTB and FIX in one of the constructs. A furin
 cleavage site was also introduced along with the GPGP hinge in the second
 construct. The cDNA sequence encoding F.IX was obtained from the American
 Type Culture Collection and amplified using sequence-specific restriction-site
 flanking primers and a cDNA clone of human factor IX as template. The PCR
 product was then cloned into the pCR Bluntll Topo vector (Invitrogen) and the
 sequence was verified. Following Smal/Xbal digestion, the FIX gene was ligated
 into the pLD Ctv 5CP chloroplast transformation vector (14) to create pLD-CTB
 FIX (only a GPGP hinge between CTB and FIX) and pLD-CTB FFIX (with a GPGP
 hinge and furin cleavage site between CTB and FIX) vectors.
 Regenerati n of Transplastomic Plants and Confirmation of Transgene Integration
 b  Southern Blot. Transplastomic plants using chloroplast expression vectors pLD
 CTB-FIX and pLD CTB-FFIX were regenerated as described elsewhere (12, 22).
 Total plant DNA (1-2 ug) isolated from leaves using a Qiagen DNeasy Plant
 Mini Kit was digested with Hindlll, and Southern blot analysis was carried out
 to confirm integration and determine homoplasmy as described previously
 (22). Southern blots were hybridized with a [32P]oc[dCTP]-labeled chloroplast
 flanking sequence probe (0.81 kb) containing the trn\-trnA genes. The trans
 plastomic plants with roots were transferred to a greenhouse as described
previously (12).
 Immunoblot Analysis. Young, mature, and old leaves from transformed plants
 grown in a greenhouse were collected at 10 AM, 2 PM, and 6 PM. Chloroplast
 derived CTB-FIX and CTB-FFIX proteins were extracted from 100 mg of pow
 dered leaf material as described earlier (12,22). Equal amounts of total protein
 along with known amounts of purified bacterial CTB (Sigma) were separated
 by SDS/PAGE and transferred to a nitrocellulose membrane by electroblotting.
 Immunoblotting with rabbit anti-CTB primary polyclonal antibody (1:3,000;
 Sigma) and h seradish peroxidase (HRP) -conjugated donkey anti-rabbit
 secondary antibody (1:5,000; Southernbiotech) was used for densitometric
 analysis (12, 16, 19). A SuperSignal West Pico HRP Substrate Kit (Pierce) was
 employed for detection of chemiluminescence signal by exposure to film.
 Fusion protein was also detected using goat anti-human factor IX (1:3,000;
 Enzyme Research) antibody followed by donkey anti-goat IgG-HRP
 conjugated secondary antibody (1:5,000; Santa Cruz Biotechnology). Native
 PAGE was also carried out and fusion protein was detected as described above.
 GM1 receptor binding assays were performed as described previously (40).
 Animal Experiments. Male C3H/HeJ mice with targeted deletion of the F9 gene
 (hemophilia B mice, 8-10 weeks old at the onset of experiments) were used
 o
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 as published (26, 41). Animals were housed under special pathogen-free
 conditions at the University of Florida and treated under Institutional Ani
 mal Care and Use Committee-approved protocols. The leaf material for oral
 delivery was ground in liquid nitrogen with mortar and pestle and stored at
 -80 ?C until the day of administration. Oral doses (250 mg each) of either
 untransformed or transgenic leaf material were resuspended in 200 pL of
 sterile PBS and homogenized on ice for 5 min with an OMNI International
 (GLH-2596) probe. The plant cell suspension was stored on ice until oral
 delivery via oral gavage using a tuberculin syringe and a 20-G bulb-tipped
 gastric gavage needle (Popper and Sons) while maintaining the animals
 under light anesthesia. Recombinant hF.IX (Benefix) was injected into the
 tail vein at 1 IU (4-5 ug hF.IX) per mouse. Plasma samples were collected by
 tail bleed into citrate buffer as described (26). For clearance studies, mice
 were bled from the retro-orbital plexus using heparinized microcaplllary
 tubes. To block anaphylactic reactions, 150 pg antihistamine (triprolidine;
 Sigma) and 50 pg antiplatelet-activating factor (PAF) CV-3988 were coin
 jected i.v. (in 100 pL PBS) 5 min before administration of hF.IX.
 Antigen and Antibody Measurements. Plasma levels of hF.IX antigen were
 measured by ELISA and inhibitory antibody titers were determined by Bethesda
 assay as published (26). One Bethesda unit (BU) represents the degree of inhibition
 that results in 50% residual coagulation activity. Immunocapture assays to
 determine titers of hF.IX-specif ic Ig subclasses were as described using IgA, IgE,
 lgG1, lgG2a, and lgG2b standards from Sigma. To measure IgE titers, IgG was
 removed from plasma samples using protein G agarose (Pierce; Thermo Scientific)
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